WO1992018154A1 - Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain - Google Patents

Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain Download PDF

Info

Publication number
WO1992018154A1
WO1992018154A1 PCT/US1992/003122 US9203122W WO9218154A1 WO 1992018154 A1 WO1992018154 A1 WO 1992018154A1 US 9203122 W US9203122 W US 9203122W WO 9218154 A1 WO9218154 A1 WO 9218154A1
Authority
WO
WIPO (PCT)
Prior art keywords
igfbp
hbd
igf
bone
patient
Prior art date
Application number
PCT/US1992/003122
Other languages
English (en)
Inventor
Subburaman Mohan
David J. Baylink
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Priority to JP4510060A priority Critical patent/JP2527896B2/ja
Priority to AU17844/92A priority patent/AU658187B2/en
Publication of WO1992018154A1 publication Critical patent/WO1992018154A1/fr
Priority to FI934588A priority patent/FI934588A0/fi
Priority to KR93703181A priority patent/KR0129864B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the portion(s) of hBD-IGFBP protein which bind hydroxyapatite and/or IGF-II may be identified by a variety of methods, such as by treating purified hBD-IGFBP with a protease or a chemical agent to fragment it and determine which fragment is able to bind to labeled IGF-II or hydroxyapatite. Polypeptides may then be synthesized and used as antigen, to inhibit IGF-II or hydroxyapatite-hBD-IGFBP interaction, etc. It should be understood that as used herein, reference to hBD- IGFBP is meant to include the proteins, polypeptides, and fragments thereof unless the context indicates otherwise.
  • the invention provides screening procedures for identifying agonists or antagonists of events mediated by the ligand/hBD-IGFBP interaction.
  • screening assays may employ a wide variety of formats, depending to some extent on which aspect of the ligand/binding protein interaction is targeted. For example, such assays may be designed to identify compounds which bind to the binding protein and thereby block or inhibit interaction with the IGF-II or hydroxyapatite. Other assays can be designed to identify compounds which can substitute for hBD-IGFBP. Yet other assays can be used to identify compounds which inhibit or facilitate the association of IGF to hBD-IGFBP and thereby mediate the cellular response to IGF.
  • hBD-IGFBP Human bone extract was subjected to hydroxyapatite (HA) chromatography in 4 M guanidine HCl as described in Mohan, et al., ibid.
  • An IGF-II affinity column was constructed by coupling 250 ⁇ g of IGF-II purified from human bone to cyanogen bromide-activated Sepharose 4B beads.
  • the column was then extensively washed with potassium phosphate buffer to completely remove the unbound proteins.
  • the bound proteins were eluted with 20-25 ml of 30 mM tris-acetate (pH 7.2)/4 M guanidine-HCl.
  • the affinity bound fraction was concentrated in an Amicon cell using a YM 5 membrane and then dialyzed against 20 mM tris-HCl (pH 8.0) buffer.
  • the dialyzed affinity bound fraction was applied to a Pharmacia FPLC Mono Q anion exchange column previously equilibrated with the tris-HCl buffer.
  • the bound proteins were eluted with a linear gradient from 0-1 M NaCl in 20 mM tris-HCl buffer in 100 min.

Abstract

Compositions purifiées et isolées d'une protéine de liaison pour facteurs de croissance analogues à l'insuline (IGFs) I et II. La protéine de liaison, connue sous l'appellation de protéine de liaison d'IGF dérivée d'os humain (hBD-IGFBP), potentialise les effets prolifératifs de IGF-II sur des cellules osseuses. L'invention concerne également des méthodes de diagnostic pour hBD-IGFBP, ainsi que des compositions pharmaceutiques et des procédés de traitement de troubles osseux, de cicatrisation de lésions, de réparation de la peau, et de modulation de l'activité des IGF dans les os.
PCT/US1992/003122 1991-04-19 1992-04-15 Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain WO1992018154A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP4510060A JP2527896B2 (ja) 1991-04-19 1992-04-15 ヒト骨由来インスリン様成長因子結合タンパク
AU17844/92A AU658187B2 (en) 1991-04-19 1992-04-15 Human bone derived insulin like growth factor binding protein
FI934588A FI934588A0 (fi) 1991-04-19 1993-10-18 Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
KR93703181A KR0129864B1 (en) 1991-04-19 1993-10-19 Human bore devived insulin like growth factor binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68835391A 1991-04-19 1991-04-19
US688,353 1991-04-19

Publications (1)

Publication Number Publication Date
WO1992018154A1 true WO1992018154A1 (fr) 1992-10-29

Family

ID=24764088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/003122 WO1992018154A1 (fr) 1991-04-19 1992-04-15 Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain

Country Status (11)

Country Link
EP (1) EP0580752A4 (fr)
JP (1) JP2527896B2 (fr)
KR (1) KR0129864B1 (fr)
AU (1) AU658187B2 (fr)
CA (1) CA2107475A1 (fr)
CZ (1) CZ283601B6 (fr)
FI (1) FI934588A0 (fr)
HU (1) HUT70297A (fr)
NO (1) NO933742L (fr)
RU (1) RU2114120C1 (fr)
WO (1) WO1992018154A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
EP0800530A1 (fr) * 1994-07-20 1997-10-15 Celtrix Pharmaceuticals, Inc. Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
US6500635B1 (en) 1991-01-08 2002-12-31 Chiron Corporation Insulin-like growth factor binding protein (IGFBF-5)
US6903078B1 (en) 1995-10-11 2005-06-07 Chiron Corporation Combination PDGF, KGF, IGF, and IGFBP for wound healing
US8642037B2 (en) 2001-01-05 2014-02-04 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
CN108699127A (zh) * 2015-12-31 2018-10-23 西门子医疗保健诊断公司 非重组人胰岛素-样生长因子结合蛋白浓缩物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10212614B2 (en) * 2015-12-31 2019-02-19 Facebook, Inc. Igniting network nodes in a multi-hop wireless network

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642120A (en) * 1983-03-23 1987-02-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Repair of cartilage and bones
EP0289314A2 (fr) * 1987-04-28 1988-11-02 Roche Diagnostics GmbH Emploi de IGF-II pour le traitement de désordres des os

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7907958A (nl) * 1979-10-30 1981-06-01 Wijn Adriaan Jacques De Kar of onderstel voorzien van opklapbare wielen.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642120A (en) * 1983-03-23 1987-02-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Repair of cartilage and bones
EP0289314A2 (fr) * 1987-04-28 1988-11-02 Roche Diagnostics GmbH Emploi de IGF-II pour le traitement de désordres des os

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Proc. Natl. Acad. Sci., Volume 86, issued November 1989, S. MOHAN et al., "Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium; a potential local regulator of IGF action", see the entire document, particularly the Abstract. *
See also references of EP0580752A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500635B1 (en) 1991-01-08 2002-12-31 Chiron Corporation Insulin-like growth factor binding protein (IGFBF-5)
US6906029B2 (en) 1991-01-08 2005-06-14 Chiron Corporation Insulin-like growth factor binding protein (IGFBP-5)
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
EP0800530A1 (fr) * 1994-07-20 1997-10-15 Celtrix Pharmaceuticals, Inc. Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
EP0800530A4 (fr) * 1994-07-20 1998-12-02 Celtrix Pharma Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
US6017885A (en) * 1994-07-20 2000-01-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US6903078B1 (en) 1995-10-11 2005-06-07 Chiron Corporation Combination PDGF, KGF, IGF, and IGFBP for wound healing
US8642037B2 (en) 2001-01-05 2014-02-04 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US9234041B2 (en) 2001-01-05 2016-01-12 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
CN108699127A (zh) * 2015-12-31 2018-10-23 西门子医疗保健诊断公司 非重组人胰岛素-样生长因子结合蛋白浓缩物

Also Published As

Publication number Publication date
JP2527896B2 (ja) 1996-08-28
NO933742L (no) 1993-10-18
CA2107475A1 (fr) 1992-10-20
JPH06501270A (ja) 1994-02-10
AU1784492A (en) 1992-11-17
FI934588A (fi) 1993-10-18
KR0129864B1 (en) 1998-04-09
AU658187B2 (en) 1995-04-06
CZ219093A3 (en) 1994-12-15
EP0580752A4 (en) 1994-08-24
CZ283601B6 (cs) 1998-05-13
FI934588A0 (fi) 1993-10-18
HU9302942D0 (en) 1994-01-28
HUT70297A (en) 1995-09-28
EP0580752A1 (fr) 1994-02-02
RU2114120C1 (ru) 1998-06-27

Similar Documents

Publication Publication Date Title
US5736511A (en) Methods for treatment using acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
AU623447B2 (en) Binding protein for insulin-like growth factors
JP2648951B2 (ja) 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
EP0424416B1 (fr) Sous-unite labile aux acides d'un complexe proteique de liaison du facteur de croissance analogue a l'insuline
EP0546110B1 (fr) Nouvelle proteine de liaison de facteur de croissance analogue a l'insuline igfbp-5
Perkel et al. An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP
AU658187B2 (en) Human bone derived insulin like growth factor binding protein
Ogasawara et al. Identification and purification of truncated insulin-like growth factor I from porcine uterus. Evidence for high biological potency
WO1992003470A1 (fr) Matiere genetique codant la ifgbp-5
US5453489A (en) Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly
US5919902A (en) Leptin bound to inter-alphatrypsin inhibitor and uses thereof
JPH11506337A (ja) 骨刺激因子
WO1999049894A1 (fr) Antagonistes du gene 6 specifique de l'arret de croissance, et leur utilisation contre des troubles insulinoresistants
Ogata Demonstration of pancreatic secretory trypsin inhibitor in serum-free culture medium conditioned by the human pancreatic carcinoma cell line CAPAN-1.
US5693754A (en) Inhibitory binding protein for insulin-like growth factors
US7125961B2 (en) Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
AU638935B2 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf)binding protein complex
US6329500B1 (en) Transforming growth factor-β binding site
US20030027753A1 (en) Bone stimulating factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 1992910967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2107475

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1993-2190

Country of ref document: CZ

Ref document number: 934588

Country of ref document: FI

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
ENP Entry into the national phase

Ref document number: 1993 137182

Country of ref document: US

Date of ref document: 19931112

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1992910967

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1993-2190

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1993-2190

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1992910967

Country of ref document: EP